AUDENTES THERAPEUTICS INC's ticker is BOLD and the CUSIP is 05070R104. A total of 193 filers reported holding AUDENTES THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 5.36 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $78,346,000 | +65.2% | 1,309,250 | -22.5% | 0.01% | +25.0% |
| Q3 2019 | $47,433,000 | -32.5% | 1,688,616 | -9.0% | 0.00% | -20.0% |
| Q2 2019 | $70,262,000 | +30.0% | 1,855,826 | +34.0% | 0.01% | +25.0% |
| Q1 2019 | $54,060,000 | +55.4% | 1,385,442 | -15.1% | 0.00% | +33.3% |
| Q4 2018 | $34,794,000 | -31.4% | 1,631,971 | +27.5% | 0.00% | -25.0% |
| Q3 2018 | $50,694,000 | +1.3% | 1,280,443 | -2.2% | 0.00% | 0.0% |
| Q2 2018 | $50,036,000 | +67.4% | 1,309,504 | +31.6% | 0.00% | +33.3% |
| Q1 2018 | $29,893,000 | +66.7% | 994,770 | +73.3% | 0.00% | +200.0% |
| Q4 2017 | $17,937,000 | +153.7% | 573,961 | +127.5% | 0.00% | 0.0% |
| Q3 2017 | $7,070,000 | +67.0% | 252,284 | +14.0% | 0.00% | – |
| Q2 2017 | $4,234,000 | +272.4% | 221,276 | +231.6% | 0.00% | – |
| Q1 2017 | $1,137,000 | -1.2% | 66,732 | +6.0% | 0.00% | – |
| Q4 2016 | $1,151,000 | +82.1% | 62,980 | +77.4% | 0.00% | – |
| Q3 2016 | $632,000 | – | 35,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 2,485,000 | $69,804,000 | 6.41% |
| Versant Venture Management, LLC | 553,916 | $15,559,500,000 | 6.02% |
| Foresite Capital Management III, LLC | 315,331 | $8,858,000 | 3.38% |
| Opaleye Management Inc. | 285,000 | $8,006,000 | 2.90% |
| Redmile Group, LLC | 2,962,655 | $83,221,000 | 2.78% |
| Casdin Capital, LLC | 860,000 | $24,157,400,000 | 2.50% |
| Sofinnova Investments, Inc. | 933,640 | $26,226,000 | 2.37% |
| Eversept Partners, LP | 253,726 | $7,127,163 | 2.21% |
| PFM Health Sciences, LP | 2,315,938 | $65,055,000 | 1.92% |
| Global Endowment Management, LP | 581,488 | $16,334,000 | 1.43% |